作者:Nichola J. Arnold、Ruth Arnold、David Beer、Gurdip Bhalay、Stephen P. Collingwood、Sarah Craig、Nicholas Devereux、Mark Dodds、Andrew R. Dunstan、Robin A. Fairhurst、David Farr、Joseph D. Fullerton、Angela Glen、Sylvie Gomez、Sandra Haberthuer、Julia D.I. Hatto、Colin Howes、Darryl Jones、Thomas H. Keller、Beate Leuenberger、Heinz E. Moser、Irene Muller、Reto Naef、Paul A. Nicklin、David A. Sandham、Katharine L. Turner、Morris F. Tweed、Simon J. Watson、Mauro Zurini
DOI:10.1016/j.bmcl.2006.11.019
日期:2007.4
Inhibitors of PDE5 are useful therapeutic agents for treatment of erectile dysfunction. A series of novel xanthine derivatives has been identified as potent inhibitors of PDE5, with good levels of selectivity against other PDE isoforms, including PDE6. Studies in the dog indicate excellent oral bioavailability for compound 21.
PDE5抑制剂是治疗勃起功能障碍的有用治疗剂。已鉴定出一系列新的黄嘌呤衍生物作为PDE5的有效抑制剂,对其他PDE异构体(包括PDE6)具有良好的选择性。在狗中进行的研究表明,化合物21具有出色的口服生物利用度。